Clinical trials: Hematologic
Anemia, Liver Disease
Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia
The purpose of the study is to evaluate the safety and tolerability of pegylated interferon alpha-2b (PEG-Intron) in patients with severe complications related to Hereditary hemorrhagic telangiectasia (HHT).
- Conditions
- Anemia, Liver Disease, Hypoxemia
- Trial name
- NCT00588146
- Testing
- Pegylated Interferon Alpha2b, Standard care
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Mayo Clinic
Multiple Myeloma, Plasma Cell Leukemia
Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants
The primary objectives of this study are to: To determine the maximum tolerated dose (MTD) of bortezomib in combination with high-dose melphalan as a conditioning regimen.
- Trial name
- NCT00307086
- Testing
- Bortezomib, Melphalan, PBSCT
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Waldenstrom Macroglobulinemia
Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia
This research study is studying a targeted therapy as a possible treatment for relapsed or refractory Waldenstrom's Macroglobulinemia (WM). This study is using the study intervention ABT-199.
- Trial name
- NCT02677324
- Testing
- ABT199
- Where
- 4 sites in United States
- Volunteers
- 33 people
- Sponsor
- Dana-Farber Cancer Institute
Waldenstrom Macroglobulinemia, DASATINIB
Dasatinib In Waldenström Macroglobulinemia
This is Phase I pilot, single center study designed to explore the safety of Dasatinib in symptomatic Waldenström Macroglobulinemia participants who are progressing on ibrutinib therapy with BTK Cys481 or PLCG2 mutations
- Trial name
- NCT04115059
- Testing
- Dasatinib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Jorge J. Castillo, MD
Thrombotic Thrombocytopenic Purpura
Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura
This is a single group, treatment, Phase 3, open-label, single-arm study to evaluate the efficacy and safety of caplacizumab and immunosuppressive therapy (IST) without firstline therapeutic plasma exchange (TPE) with primary…
- Trial name
- MAYARI (NCT05468320)
- Testing
- Caplacizumab, Corticosteroids, anti-CD20 antibody
- Where
- 27 sites in United States, Belgium and 9 more
- Volunteers
- 51 people
- Sponsor
- Sanofi
Leukemia, Myeloid, Chronic, Lymphomas
Post Transplant Donor Lymphocyte Infusion
The purpose of this study is to test the hypothesis that a pre-infusion preparative regimen of cyclophosphamide and fludarabine will improve the effectiveness of DLI in patients with blood cancers.
- Conditions
- Leukemia, Myeloid, Chronic, Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome
- Trial name
- NCT00167180
- Testing
- Donor Lymphocyte Infusion, Induction Chemotherapy
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Bleeding Disorder, Stroke, Ischemic
XIENCE 28 Global Study
XIENCE 28 Global Study is a prospective, single arm, multi-center, open label, non-randomized trial to further evaluate the safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of…
- Conditions
- Bleeding Disorder, Stroke, Ischemic, Stroke Hemorrhagic, Hematological Disease
- Trial name
- NCT03355742
- Testing
- XIENCE, DAPT
- Where
- 52 sites in Austria, Belgium and 11 more
- Volunteers
- 963 people
- Sponsor
- Abbott Medical Devices
Eosinophilic Esophagitis (EoE)
Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)
This is a continuation study of Budesonide Oral Suspension (BOS) in adults and adolescents with Eosinophilic Esophagitis (EoE) who have completed participation in the SHP621-302 extension study.
- Trial name
- NCT03245840
- Testing
- Budesonide oral suspension
- Where
- 45 sites in United States
- Volunteers
- 133 people
- Sponsor
- Shire
Barrett's Esophagus, Eosinophilic Esophagitis
Study to Image the Esophagus Using the OFDI Capsule
The main purpose of this research is to test the feasibility and tolerability of the tethered capsule Optical Frequency Domain Imaging (OFDI)
- Trial name
- NCT02204150
- Testing
- OFDI Capsule
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Anemia
Age of Blood in Children in Pediatric Intensive Care Units
ABC PICU is a randomized clinical trial that will compare the clinical consequences of RBC storage duration in 1538 critically ill children.
- Trial name
- ABC-PICU (NCT01977547)
- Testing
- Short storage RBC age
- Where
- 37 sites in United States, Canada and 3 more
- Volunteers
- 1,538 people
- Sponsor
- Washington University School of Medicine
Hematologic Malignancies, Acute Leukemia
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
This is a research study involving the treatment of patients with hematological cancers with allogeneic (cells from a donor) hematopoietic stem cell transplant (HSCT). HSCT is often referred to as bone marrow transplant.
- Conditions
- Hematologic Malignancies, Acute Leukemia, Myelodysplastic Syndromes (MDS) Other Than RA or RARS Subtypes, Hodgkin's Lymphoma
- Trial name
- NCT01350258
- Testing
- Fludarabine, Thiotepa, Total Body Irradiation (TBI)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Sorafenib in Myelodysplastic Syndrome
The purpose of this study is to evaluate the efficacy of sorafenib in patients with Myelodysplastic Syndrome (MDS). Eligible subjects will receive Sorafenib administered at 400mg orally twice a day, given on days 1-28 of a 28-day…
- Trial name
- NCT00510289
- Testing
- Sorafenib
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Duke University
Hemophilia B
Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B
Phase 2b, single-center, open-label study designed to evaluate the pharmacokinetics, pharmacodynamics, efficacy and safety of subcutaneous (SC) prophylaxis treatment regimens with CB2679d in 6 adult, male subjects with severe…
- Trial name
- NCT03995784
- Testing
- Coagulation Factor IX variant
- Where
- South Africa
- Volunteers
- 6 people
- Sponsor
- Catalyst Biosciences
AL Amyloidosis
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down.
- Trial name
- NCT04512235
- Testing
- CAEL-101, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen
- Where
- 110 sites in United States, Australia and 17 more
- Volunteers
- 281 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Plasma Cell Myeloma, Residual Disease
Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant
This randomized phase II trial studies how well lenalidomide alone compared to lenalidomide, ixazomib citrate, and dexamethasone work in treating patients with multiple myeloma that remains (residual) after donor stem cell…
- Trial name
- NCT02389517
- Testing
- Ixazomib Citrate, Lenalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Chicago
Haemophilia A
BAY81-8973 Pediatric Safety and Efficacy Trial
The primary objective was to evaluate the safety and efficacy of the treatment with BAY81-8973 for prophylaxis and treatment of breakthrough bleeds in children with severe hemophilia A.
- Trial name
- NCT01311648
- Testing
- Recombinant Factor VIII (Kovaltry, BAY81-8973)
- Where
- 43 sites in United States, Argentina and 15 more
- Volunteers
- 94 people
- Sponsor
- Bayer
Leukemia, Myelofibrosis
CEP-701 for PH-negative Myelofibrosis
The goal of this clinical research study is to find out if CEP-701 can help control myelofibrosis (MF). The safety of CEP-701 will also be studied.
- Trial name
- NCT00494585
- Testing
- CEP-701
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- M.D. Anderson Cancer Center
Adult Acute Lymphoblastic Leukemia in Remission, Adult Grade III Lymphomatoid Granulomatosis
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
This clinical trial studies etoposide, filgrastim and plerixafor in improving stem cell mobilization in patients with non-Hodgkin lymphoma.
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
- Trial name
- NCT01408043
- Testing
- plerixafor, filgrastim, etoposide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Case Comprehensive Cancer Center
Leukemia
S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
RATIONALE: Monoclonal antibodies, such as epratuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00945815
- Testing
- epratuzumab, clofarabine, cytarabine
- Where
- 81 sites in United States
- Volunteers
- 35 people
- Sponsor
- SWOG Cancer Research Network
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
This study is to determine the efficacy of momelotinib (MMB) versus ruxolitinib (RUX) in participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (post-PV/ET MF) who…
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
- Trial name
- Simplify 1 (NCT01969838)
- Testing
- Momelotinib, Ruxolitinib
- Where
- 114 sites in United States, Australia and 20 more
- Volunteers
- 432 people
- Sponsor
- Sierra Oncology LLC - a GSK company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.